FDA’s Post

📣‼️ The Union for International Cancer Control (UICC) was founded in 1933 as a call to action on cancer. 👉🏼 World Cancer Day 2024 is the third and final of their "Close the care gap" campaign, created as a call to action for governments to reduce inequities related to patient access to quality cancer care and services. 👉🏼 Please join US FDA Oncology Center of Excellence, the European Medicines Agency, and #patients for a panel discussion on regulatory programs that quicken therapeutic access to patients. #cancer #cancertreatment #patientcare #patientcentricity 👇🏼

Findings presented in Chicago at the annual meeting of the American Society of Clinical Oncology (ASCO) significantly broadened the range of breast cancer patients that could benefit from Enhertu, an antibody-drug conjugate designed to deliver toxic chemotherapy directly to tumours. The data showed an “unprecedented” improvement in progression-free survival, supporting the thesis that antibody-drug conjugates can deliver their payloads more specifically to cancer cells. AstraZeneca and Daiichi Sankyo Canada’s Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy – even if they had very low levels of the mutant protein targeted by the drug, according to trial results. Read more on this at: https://lnkd.in/dt7j7bhf Kim MacDonald #breastcancercanada #breastcancerresearch #breastcancerprogress #enhertu #ASCO24 #BCCatASCO24

We are pleased to announce presentations of four of our clinical studies at the American Society of Clinical Oncology annual congress at Chicago. Our presentations this year include data of investigational drugs olverembatinib in patients with SDH deficient gastrointestinal stromal tumor (GIST), an indication that currently has no effective treatment; lisaftoclax in patients with acute myeloid leukemia (AML) and in patients with Waldenstrom macroglobulinemia (WM), as well as those of APG-2449 in patients with non-small cell lung cancer (NSCLC). We remain committed to bring novel and effective therapies for patients with cancers. We are currently conducting more than 40 clinical trials including 5 global registrational phase III trials in the US, Australia, Europe, and China. #ASCO #cancer #cancerresearch #drugdevelopment https://lnkd.in/eBxbAyuR

Results from our Phase 3 clinical trial evaluating treatments for patients with advanced ALK-positive NSCLC shared at American Society of Clinical Oncology (ASCO) 2024 Albert Bourla Pfizer #ASCO24 #Cancer #LCSM #NSCLC #ClinicalTrials #OncoDaily #Oncology

We are happy to announce our return to the "Invest in Oncology Forum" for the second time, where we will be among Nordic companies pioneering advanced therapies in the field of cancer. At the forum, we are excited to showcase the latest developments of iadademstat, the most potent LSD1 inhibitor currently in clinical development for cancer treatment. Specifically, we will highlight the progress of our ongoing FRIDA trial in AML R/R-Flt3+ patients. Furthermore, we are thrilled to introduce the first outcome of our CRADA collaborative efforts with the NCI-NIH. This collaboration has resulted in the initiation of the first clinical trial where we combine iadademstat with atezolizumab or durvalumab in 1L-ED SCLC patients. This marks a significant milestone in our commitment to advancing innovative treatment approaches in oncology. #LSD1 #epigenetics #personalizedmedicine #iadademstat #AML #SCLC #ICIs #gilteritinib #durvalumab #atezolizumab #oryzon 

🌟 Exciting News! 🌟 I am thrilled to announce the publication of our latest article in the American Journal of Clinical Oncology: **"Efficacy and Safety of BRCA-targeted Therapy (Polyadenosine Diphosphate-ribose Polymerase Inhibitors) in the Treatment of BRCA-mutated Breast Cancer: A Systematic Review and Meta-analysis."** In this comprehensive study, we delve into the therapeutic potential of PARP inhibitors for patients with BRCA-mutated breast cancer, evaluating both their efficacy and safety. Our findings provide valuable insights that can help guide clinical decisions and improve patient outcomes. 🔍 **Key Highlights:** - Systematic review and meta-analysis of the latest clinical trials - Detailed evaluation of the therapeutic benefits and adverse effects of PARP inhibitors - Implications for personalized treatment strategies in BRCA-mutated breast cancer I want to extend my heartfelt thanks to my co-authors and collaborators for their dedication and hard work. Your expertise and commitment made this research possible. Read the full article here: [Efficacy and Safety of BRCA-targeted Therapy](https://lnkd.in/gbWf2j5M) #breastcancer #BRCA #PARPinhibitors #oncology #clinicalresearch #systematicreview #metaanalysis

At #AmplityHealth, our contract sales, medical, and communications experts have a front-row seat in advancing #immunotherapy and #precisionmedicine to combat cancer more effectively with our biopharma clients. Here are some key highlights from #ASCO24 Day 1: - Discussion of newly FDA-approved oncology agents - Presentation of 5 years of data from the CROWN study comparing lorlatinib and crizotinib in new patients with advanced ALK-positive non-small cell lung cancer - Analysis of research into whether circulating tumor DNA can help predict the effectiveness of neoadjuvant chemotherapy and evaluate the prognosis for those with early breast cancer View our full Day 1 summary and join our mailing list for updates: https://lnkd.in/gA3s6Gh7

That’s a wrap – thank you American Society of Clinical Oncology (ASCO)! During #ASCO2024, we presented data on mRNA-4157 (V940), our investigational individualized neoantigen therapy, which is being evaluated in a comprehensive development program with our partner Merck. We have initiated Phase 3 studies in patients with high-risk #melanoma and non-small cell lung cancer, in addition to Phase 2 studies in patients with renal cell carcinoma and urothelial carcinoma and a Phase 2/3 study for cutaneous squamous cell #carcinoma. The future of #cancer treatment is evolving, and #mRNA is at the forefront. Together, we can revolutionize oncology.

At #AmplityHealth, our contract sales, medical, and communications experts have a front-row seat in advancing #immunotherapy and #precisionmedicine to combat cancer more effectively with our biopharma clients. Here are some key highlights from #ASCO24 Day 1: - Discussion of newly FDA-approved oncology agents - Presentation of 5 years of data from the CROWN study comparing lorlatinib and crizotinib in new patients with advanced ALK-positive non-small cell lung cancer - Analysis of research into whether circulating tumor DNA can help predict the effectiveness of neoadjuvant chemotherapy and evaluate the prognosis for those with early breast cancer View our full Day 1 summary and join our mailing list for updates: https://lnkd.in/euzvmUPG

Tissue-agnostic precision medicine takes the spotlight! - Vivek Subbiah, MD American Society of Clinical Oncology (ASCO) #JCOPO #Cancer #EuropeanMedicinesAgency #FDA #Oncology #Selpercatinib #JournalOfClinicalOncology #OncoDaily  #PrecisionOncology